Ropes & Gray advised Gilead Sciences, Inc. on a definitive agreement to acquire Arcellx for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases. The transaction was announced in a Feb. 23 press release.
Headquartered in Foster City, California, Gilead Sciences, Inc. is a biopharmaceutical company that has achieved breakthroughs in medicine for more than three decades and operates in more than 35 countries.
The team was led by mergers & acquisitions partner Emily Oldshue and counsel Nick Roper, and included executive compensation & employee benefits partner Renata Ferrari, IP transactions partner Megan Baca, tax partners Benjamin Rogers and David Saltzman, health care partner Christine Moundas, life sciences regulatory & compliance partner Josh Oyster, and real estate partner David Kaye.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.